VipharmS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-10-04
Share capital
4 156 700,00 PLN
Activity description

Vipharm is a Polish pharmaceutical company that specializes in the research, production, and promotion of generic and oncological drugs. It focuses on medications used in oncology, palliative care, hematology, neurology, psychiatry, and diabetology, addressing various conditions such as cancer, mental health disorders, and neurological diseases. The company aims to ensure the availability of its products and engages in educational activities for healthcare professionals and patients.

Registered address
A. I F. Radziwiłłów 9, 05-850 Ożarów Mazowiecki, Poland
Website
vipharm.plWebsite active
Email
Email address current
Electronic delivery address
AE:PL-86743-79733-EDDGW-18

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 30.66mMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 1.35mMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 26.15mMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 27.57mMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 2004-02-01. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$1.1M
Buildings and premises
$1.6M

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$897.5K
Aid for research and development projects: industrial research
$664.3K
Aid for research and development projects: experimental development
$25,768

European Funds

ProjectEU co-financing
Opracowanie innowacyjnej technologii wytwarzania produktu leczniczego o działaniu immunomodulującm i neuroprotekcyjnym
$690.1K
Opracowanie innowacyjnej technologii wytwarzania przeciwnowotworowego produktu leczniczego inhibitora różnych receptorowych kinaz tyrozynowych.
$534.6K

Tenders

No recorded participation in tenders.

Trademarks

Vipharm holds 23 active trademarks registered with the Polish Patent Office. 6 marks have expired or were not registered. The first mark was filed in 1998.

MarkProtected until
ANSIFORA(word)Sep 30, 2032
Tiralevam(word)Jun 22, 2030
ASTEXANA(word)Jul 16, 2029
Miraklide(word)May 21, 2029
Alkapidon(word)Mar 2, 2029

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Agnieszka Szelejewska – Attorney-in-fact (sole)
Jan Szelejewski – President of the Management Board

Manner of representation

A member of the management board or a commercial proxy independently.

Supervisory board

Alina Wolnicka – Supervisory Board Member
Irena Maria Szelejewska – Supervisory Board Member
Jolanta Moszczyńska Paterczyk – Supervisory Board Member
Maria Kosek – Supervisory Board Member
Krzysztof Sołtysiak – Supervisory Board Member

Beneficial owners

Person

Change history

DateEvent
2012-03-15Address change
2011-12-06Address change
2010-09-29Share capital change
2004-10-13Share capital change
2004-01-20Address change

FAQ

Last updated: 2026-07-09